M. Jay-Smith et al. / Tetrahedron xxx (2016) 1e12
11
4.1.1.
a
-Phenyl-
a
-[6-phenyl-6-(2-pyridyl)-2-fulvenyl]-2-
tetrahydrofuran (25 mL). Purification by column chromatography
(hexane/ethyl acetate, 1:2) afforded 1b (white solid; 1.0 g,
1.95 mmol, 70%) as a mixture of eight stereoisomers. Rf (hexane/
ethyl acetate, 1:2): 0.35, 0.26, 0.20, 0.15; mp 131e143 ꢀC; 1H NMR
pyridinemethanol (4).4 As used to determine the effect of temper-
ature, concentration, reaction solvent and Lewis acid on the Diel-
seAlder reaction of racemic 2-fulvenylmethanol 4 and maleimide
(6). To a freshly prepared solution of sodium ethoxide (26 mmol;
from 0.60 g sodium) in ethanol (30 mL) at 0 ꢀC was added 2-
benzoylpyridine (2) (9.15 g, 52 mmol), followed by freshly dis-
tilled cyclopentadiene (3) (1.72 g, 26 mmol), added dropwise over
60 min, and the mixture stirred at 10 ꢀC for a further 6 h. The so-
lution was then concentrated in vacuo with purification by column
chromatography (petroleum ether/ethyl acetate, 4:1) affording 4
(orange solid; 8.89 g, 21 mmol, 82%) as a racemic mixture of four
stereoisomers. Rf (petroleum ether/ethyl acetate, 1:1): 0.56; mp
157e162 ꢀC (Lit.4 160e165 ꢀC); nmax(neat) cmꢃ1 3376, 3079, 1589,
(400 MHz, CDCl3): d 2.89e3.07 (0.35H, m, S/H-2, T/H-2, X/H-2, R/H-
2, X/H-3, S/H-3), 3.26e3.28 (0.05H, m, T/H-3), 3.35e3.56 (0.96H, m,
V/H-2, U/H-2, Y/H-3, U/H-3, W/H-3, R/H-3, S/H-4), 3.62e3.69
(0.88H, m, Y/H-2, W/H-2, V/H-3, W/H-4), 3.73e3.78 (0.20H, m, R/H-
1, X/H-1, T/H-4), 3.83e3.88 (0.28H, m, V/H-1, U/H-1), 3.94e3.98
(0.35H, m, Y/H-4, X/H-4), 4.11e4.16 (0.16H, m, U/H-4, R/H-4),
4.31e4.33 (0.20H, m, V/H-4), 4.35e4.38 (0.09H, m, T/H-1, S/H-1),
4.44e4.47 (0.48H, m, Y/H-1, W/H-1), 5.62e5.66 (0.76H, m, V/H-6,
Y/H-6, U/OH, W/OH), 5.74e5.76 (0.13H, m, R/H-6, T/H-6), 5.80
(0.04H, s, S/OH), 5.83 (0.28H, s, Y/OH), 5.86 (0.07H, s, X/OH), 5.88
(0.20H, s, V/OH), 6.05e6.08 (0.28H, m, U/H-6, W/H-6), 6.15 (0.07H,
dd, J¼3.4, 1.1 Hz, X/H-6), 6.19 (0.05H, T/OH), 6.20 (0.04H, dd, J¼3.4,
1.1 Hz, S/H-6), 6.54 (0.08H, s, R/OH), 6.77e7.57 (16H, m, Ar),
1568, 1431, 1371, 1150, 1035, 952, 755; 1H NMR (CDCl3):
d 5.99e6.00
(0.5H, m, trans H-1), 6.02e6.04 (0.5H, m, cis H-1), 6.16 (1H, br s,
OH), 6.33e6.36 (0.5H, m, cis H-4), 6.38e6.41 (0.5H, m, trans H-4),
6.55e6.58 (1H, m, H-3), 7.14e7.67 (16H, m, Ar), 8.52 (1H, d,
7.67e7.95 (1H, m, NH), 8.39e8.63 (2H, m, Pyr).
a
J¼4.8 Hz,
a
Pyr), 8.59 (0.5 H, d, J¼4.9 Hz, cis
aPyr), 8.68 (0.5H, d,
J¼4.9 Hz, trans
aPyr).
4.1.5. 5-( -Hydroxy- -2-pyridylbenzyl)-7-(a-2-pyridylbenzylidene)-
a
a
5-norbornene-2,3-dicarboximide (1c).4 Compound 1c was prepared
according to method B using racemic 2-fulvenylmethanol 4 (1.04 g,
2.51 mmol) and maleimide (6) (244 mg, 2.51 mmol) in methanol
(20 mL). Purification by column chromatography (hexane/ethyl ace-
tate,1:2) afforded 1c (white solid; 1.11 g, 2.17 mmol, 87%) as a mixture
of eight stereoisomers. Rf (hexane/ethyl acetate,1:2): 0.35, 0.26, 0.20,
4.1.2. -Phenyl-a-[6-phenyl-6-(2-pyridyl)-2-fulvenyl]-2-
a
pyridinemethanol bis-N-oxide (13).42 Prepared as a racemic mixture
for use as an HPLC reference in the asymmetric synthesis of com-
pound 13. To a solution of 1226 (136 mg, 0.68 mmol) in ethanol/
tetrahydrofuran (0.7 mL, 1:1 v/v) at 10 ꢀC was added dropwise
a solution of cyclopentadienyl sodium in tetrahydrofuran (0.17 mL,
0.34 mmol, 2 M) over 30 min, and the mixture stirred at 10 ꢀC for
a further 2 h. The solution was then concentrated in vacuo, the
resulting residue dissolved in methanol, filtered through a short
plug of silica and the filtrate concentrated in vacuo. Purification by
column chromatography (dichloromethane/acetone, 3:1) afforded
13 (orange solid; 109 mg, 0.20 mmol, 59%) as a racemic mixture of
four stereoisomers. Rf (dichloromethane/acetone, 3:1): 0.13; mp
180 ꢀC (dec) (Lit.42 223e224 ꢀC (EtOH/H2O)); nmax(neat) cmꢃ1 3055,
0.15; mp 131e145 ꢀC; 1H NMR (400 MHz, CDCl3):
d 2.90e3.00 (0.47H,
m, S/H-2, T/H-2, X/H-2, R/H-2), 3.04e3.10 (0.21H, m, X/H-3, S/H-3),
3.27e3.29 (0.10H, m, T/H-3), 3.36e3.60 (0.85H, m, V/H-2, U/H-2, Y/H-
3, U/H-3, W/H-3, R/H-3, S/H-4), 3.63e3.71 (0.58H, m, Y/H-2, W/H-2,
V/H-3, W/H-4), 3.74e3.75 (0.16H, m, R/H-1), 3.77e3.80 (0.23H, m, X/
H-1, T/H-4), 3.84e3.88 (0.22H, m, V/H-1, U/H-1), 3.94e4.00 (0.31H,
m, Y/H-4, X/H-4), 4.12e4.17 (0.24H, m, U/H-4, R/H-4), 4.32e4.39
(0.32H, m, T/H-1, S/H-1, V/H-4), 4.44e4.48 (0.31H, m, Y/H-1, W/H-1),
5.63e5.67 (0.53H, m, V/H-6, Y/H-6, U/OH, W/OH), 5.75e5.77 (0.26H,
m, R/H-6, T/H-6), 5.80 (0.08H, s, S/OH), 5.83 (0.18H, s, Y/OH),
5.86e5.88(0.27H, m, X/OH, V/OH), 6.06e6.09(0.21H, m, U/H-6, W/H-
6), 6.16 (0.13H, dd, J¼3.4,1.1 Hz, X/H-6), 6.19e6.21 (0.18H, m, S/H-6, T/
OH), 6.53 (0.16H, s, R/OH), 6.78e7.57 (16H, m, Ar), 7.77e7.85 (1H, m,
2924,1600,1482,1424,1253,1154, 764, 732; 1H NMR (CDCl3):
d 5.63
(0.5H, s, H-1), 6.05e6.07 (1H, m, H-1, H-4), 6.49e6.53 (1H, m, H-3,
H-4), 6.59 (0.5H, dd, J¼5.4, 1.3 Hz, H-3), 7.17e7.45 (16H, m, Ar),
8.12e8.22 (2H, m,
aPyr), 8.45 (1H, 2ꢄs, OH).
NH), 8.41e8.64 (2H, m,
aPyr).
4.1.3. 5-( -Hydroxy-a-2-pyridylbenzyl)-7-(a-2-pyridylbenzylidene)-
a
5-norbornene-2,3-dicarboximide (1a).4 Compound 1a was prepared
according to method B using racemic 2-fulvenylmethanol 4 (1.07 g,
2.58 mmol) and maleimide (6) (251 mg, 2.58 mmol) in 1,2-
dichloroethane (20 mL). Purification by column chromatography
(hexane/ethyl acetate, 1:2) afforded 1a (white solid; 1.15 g,
2.24 mmol, 87%) as a mixture of eight stereoisomers. Rf (hexane/
ethyl acetate, 1:2): 0.35, 0.26, 0.20, 0.15; mp 137e146 ꢀC; 1H NMR
4.1.6. 5-( -Hydroxy- -2-pyridylbenzyl)-7-(a-2-pyridylbenzylidene)-
a
a
5-norbornene-2,3-dicarboximide (1d).4 Compound 1d was pre-
pared according to method B using racemic 2-fulvenylmethanol 4
(1.04 g, 2.51 mmol) and maleimide (6) (244 mg, 2.51 mmol) in
dimethylsulfoxide (20 mL). Purification by column chromatography
(hexane/ethyl acetate, 1:2) afforded 1d (white solid; 880 mg,
1.72 mmol, 69%) as a mixture of eight stereoisomers. Rf (hexane/
ethyl acetate, 1:2): 0.35, 0.26, 0.20, 0.15; mp 134e145 ꢀC; 1H NMR
(400 MHz, CDCl3): d 2.89e2.99 (0.18H, m, S/H-2, T/H-2, X/H-2, R/H-
2), 3.04e3.09 (0.09H, m, X/H-3, S/H-3), 3.26e3.28 (0.03H, m, T/H-
3), 3.35e3.58 (1.02H, m, V/H-2, U/H-2, Y/H-3, U/H-3, W/H-3, R/H-
3, S/H-4), 3.62e3.69 (0.86H, m, Y/H-2, W/H-2, V/H-3, W/H-4),
3.74e3.78 (0.15H, m, R/H-1, X/H-1, T/H-4), 3.84e3.88 (0.39H, m, V/
H-1, U/H-1), 3.95e3.98 (0.34H, m, Y/H-4, X/H-4), 4.11e4.16 (0.17H,
m, U/H-4, R/H-4), 4.32e4.36 (0.34H, m, T/H-1, S/H-1, V/H-4),
4.44e4.46 (0.43H, m, Y/H-1, W/H-1), 5.63e5.66 (0.82H, m, V/H-6,
Y/H-6, U/OH, W/OH), 5.75e5.77 (0.09H, m, R/H-6, T/H-6),
5.81e5.87 (0.65H, m, Y/OH, V/OH, X/OH, S/OH), 6.06e6.08 (0.26H,
m, U/H-6, W/H-6), 6.15e6.21 (0.12H, m, X/H-6, S/H-6, T/OH), 6.53
(0.06H, s, R/OH), 6.78e7.58 (16H, m, Ar), 7.89e8.13 (1H, m, NH),
(400 MHz, CDCl3): d 2.90e3.00 (0.66H, m, S/H-2, T/H-2, X/H-2, R/H-
2), 3.03e3.10 (0.30H, m, X/H-3, S/H-3), 3.27e3.29 (0.17H, m, T/H-3),
3.35e3.59 (0.72H, m, V/H-2, U/H-2, Y/H-3, U/H-3, W/H-3, R/H-3, S/
H-4), 3.62e3.69 (0.39H, m, Y/H-2, W/H-2, V/H-3, W/H-4),
3.72e3.78 (0.52H, m, R/H-1, X/H-1, T/H-4), 3.84e3.88 (0.13H, m, V/
H-1, U/H-1), 3.95e3.98 (0.27H, m, Y/H-4, X/H-4), 4.11e4.16 (0.24H,
m, U/H-4, R/H-4), 4.33e4.34 (0.08H, m, V/H-4), 4.37e4.39 (0.31H,
m, T/H-1, S/H-1), 4.46e4.47 (0.21H, m, Y/H-1, W/H-1), 5.62e5.67
(0.34H, m, V/H-6, Y/H-6, U/OH, W/OH), 5.74e5.77 (0.36H, m, R/H-6,
T/H-6), 5.81 (0.14H, s, S/OH), 5.84 (0.11H, s, Y/OH), 5.86 (0.16H, s, X/
OH), 5.89 (0.08H, s, V/OH), 6.06e6.08 (0.15H, m, U/H-6, W/H-6),
6.16 (0.16H, dd, J¼3.4, 1.1 Hz, X/H-6), 6.20e6.21 (0.31H, m, S/H-6, T/
OH), 6.54 (0.19H, s, R/OH), 6.78e7.63 (16H, m, Ar), 7.75e7.88 (1H, m,
8.42e8.61 (2H, m,
a
Pyr).
4.1.4. 5-( -Hydroxy-
a
a
-2-pyridylbenzyl)-7-(
a
-2-pyridylbenzylidene)-
NH), 8.43e8.63 (2H, m, aPyr).
5-norbornene-2,3-dicarboximide (1b).4 Compound 1b was prepared
according to method B using racemic 2-fulvenylmethanol 4 (1.14 g,
2.75 mmol) and maleimide (6) (267 mg, 2.75 mmol) in
4.1.7. 5-(
a-Hydroxy-a-2-pyridylbenzyl)-7-(a-2-pyridylbenzylidene)-
5-norbornene-2,3-dicarboximide (1e).4 Compound 1e was prepared